Echo IQ launches EchoSolv heart disease screening platform to US market
Echo IQ’s EchoSolv enhanced screening platform is designed to support clinicians in identifying patients at risk of structural heart disease.
Sydney-based medical technology company Echo IQ (ASX: EIQ) has confirmed its flagship structural heart disease screening platform EchoSolv is now available to registered customers in the US.
The cloud-based enhanced product has been developed and rigorously tested in consultation with leading cardiologists.
It is designed to support clinicians and physicians in identifying patients with guideline-defined aortic stenosis, which is one of the most common and serious types of heart valve disease.
Echo IQ is initially introducing EchoSolv to the US market where it recently achieved positive results in a clinical effectiveness and validation study at the Beth Israel Deaconess Medical Centre within the Harvard Medical School.
The study demonstrated the platform could identify sizeable cohorts of patients with guideline-detected severe aortic stenosis as well those with a significantly heightened risk of death from the condition.
Pricing models
Echo IQ said EchoSolv would be available in two pricing models.
A “price-per-assessment” model will allow customers to conduct retrospective patient reviews and be charged for any records which are evaluated using the platform.
For customers integrating EchoSolv into their real-time clinical workflows for immediate patient assessments, Echo IQ will charge a flat monthly SaaS (software-as-a-service) fee.
The platform enables bulk assessments to be completed at a rate of up to 48,000 per minute.
The results can be exported into formats including PDF and clinicians can opt to send text or email alerts to high-risk patients.
Accurate identification
EchoSolv is designed to ensure the accurate identification of aortic stenosis in patients who would benefit from treatment or further clinical review.
The platform’s name is believed to reflect the importance of identifying at risk patients and the vital role that analysis of echocardiograms plays in meeting that challenge.
While treatment options for severe aortic stenosis are considered safe and reliable, the disease has a two-year mortality rate of 50% when left untreated.
Echo IQ chief medical advisor and cardiologist Professor David Playford said EchoSolv could potentially change the screening process for high-risk patients.
“This heralds the beginning of a new era by improving a cardiologist’s focus on patients who may be at risk, as it does not require a change of cardiac imaging solution, or new hardware, devices or interference with existing infrastructure,” he said.